A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model by Lydia Bellmann, Giuseppe Cappellano, Johanna F. Schachtl‐Riess, Anastasia Prokopi, Athanasios Seretis, Daniela Ortner, Christoph H. Tripp, Constance E. Brinckerhoff, David W. Mullins, Patrizia Stoitzner, Int. J. Cancer: 146, 1409–1420 (2020) 10.1002/ijc.32777
The Acknowledgements section is missing a reference to EU funding. The correct paragraph is the following: This work was supported by the Austrian Science Fund (FWF) with research grants to P.S. 27001‐B13 and FWF‐W1101‐B18 (L.B. is a doctoral student financed partly by this FWF‐funded PhD program). This study was supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska‐Curie grant agreement no 641549, Immutrain. We are particularly grateful to Nikolaus Romani for his continuous support. We thank Kerstin Komenda for technical support. We are grateful to Sebastian Kobold (LMU, Munich) for helpful discussion on TLR7 agonists and to Jamie Frankish for reading the manuscript.
The authors apologize for any confusion.